0H8T Stock Overview
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Aclaris Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.25 |
| 52 Week High | US$10.87 |
| 52 Week Low | US$0.61 |
| Beta | 0.23 |
| 1 Month Change | 8.26% |
| 3 Month Change | 7.33% |
| 1 Year Change | -86.56% |
| 3 Year Change | -95.46% |
| 5 Year Change | -80.57% |
| Change since IPO | -94.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0H8T | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 2.5% | -1.2% | -0.7% |
| 1Y | -86.6% | -5.0% | -1.8% |
Return vs Industry: 0H8T underperformed the UK Pharmaceuticals industry which returned -5.3% over the past year.
Return vs Market: 0H8T underperformed the UK Market which returned -2.4% over the past year.
Price Volatility
| 0H8T volatility | |
|---|---|
| 0H8T Average Weekly Movement | 9.0% |
| Pharmaceuticals Industry Average Movement | 8.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0H8T's share price has been volatile over the past 3 months.
Volatility Over Time: 0H8T's weekly volatility has decreased from 20% to 9% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 89 | Neal Walker | www.aclaristx.com |
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.
Aclaris Therapeutics, Inc. Fundamentals Summary
| 0H8T fundamental statistics | |
|---|---|
| Market cap | US$87.24m |
| Earnings (TTM) | -US$88.48m |
| Revenue (TTM) | US$31.25m |
2.8x
P/S Ratio-1.0x
P/E RatioIs 0H8T overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0H8T income statement (TTM) | |
|---|---|
| Revenue | US$31.25m |
| Cost of Revenue | US$116.47m |
| Gross Profit | -US$85.22m |
| Other Expenses | US$3.27m |
| Earnings | -US$88.48m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.25 |
| Gross Margin | -272.70% |
| Net Profit Margin | -283.15% |
| Debt/Equity Ratio | 0% |
How did 0H8T perform over the long term?
See historical performance and comparison